BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25052834)

  • 1. Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.
    Cleator JH; Duvernay MT; Holinstat M; Colowick NE; Hudson WJ; Song Y; Harrell FE; Hamm HE
    J Pharmacol Exp Ther; 2014 Oct; 351(1):33-43. PubMed ID: 25052834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA.
    Kamada A; Shimizu M; Oura K; Yoshida M; Tsuda K; Oi K; Ishigaku Y; Natori T; Narumi S; Itabashi R; Maeda T; Terayama Y
    J Stroke Cerebrovasc Dis; 2021 Mar; 30(3):105547. PubMed ID: 33360254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.
    Tourdot BE; Conaway S; Niisuke K; Edelstein LC; Bray PF; Holinstat M
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2644-50. PubMed ID: 25278289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
    Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
    J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelets Express Activated P2Y
    Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
    Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
    Tourdot BE; Stoveken H; Trumbo D; Yeung J; Kanthi Y; Edelstein LC; Bray PF; Tall GG; Holinstat M
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1632-1643. PubMed ID: 29748334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation.
    Shankar H; Garcia A; Prabhakar J; Kim S; Kunapuli SP
    J Thromb Haemost; 2006 Mar; 4(3):638-47. PubMed ID: 16460446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
    Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
    Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.
    Wu CC; Wu SY; Liao CY; Teng CM; Wu YC; Kuo SC
    Br J Pharmacol; 2010 Oct; 161(3):643-58. PubMed ID: 20880402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin-induced lysosomal exocytosis in human platelets is dependent on secondary activation by ADP and regulated by endothelial-derived substances.
    Södergren AL; Svensson Holm AC; Ramström S; Lindström EG; Grenegård M; Öllinger K
    Platelets; 2016; 27(1):86-92. PubMed ID: 25970449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects.
    Oestreich JH; Steinhubl SR; Ferraris SP; Loftin CD; Akers WS
    J Thromb Thrombolysis; 2014 Oct; 38(3):372-9. PubMed ID: 24510678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.
    Fox SC; May JA; Johnson A; Hermann D; Strieter D; Hartman D; Heptinstall S
    Platelets; 2013; 24(5):392-400. PubMed ID: 22866894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
    Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
    J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
    Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
    Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-target effect of the Epac agonist 8-pCPT-2'-O-Me-cAMP on P2Y12 receptors in blood platelets.
    Herfindal L; Nygaard G; Kopperud R; Krakstad C; Døskeland SO; Selheim F
    Biochem Biophys Res Commun; 2013 Aug; 437(4):603-8. PubMed ID: 23850619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
    Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
    Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry?
    Kassassir H; Siewiera K; Sychowski R; Watała C
    Pharmacol Rep; 2013; 65(4):870-83. PubMed ID: 24145081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
    Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
    Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
    J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.